| Ferrell-duncan Clinic Branson | |
|
525 Branson Landing Blvd Branson MO 65616-2031 | |
| (417) 875-3332 | |
| Not Available |
| Full Name | Ferrell-duncan Clinic Branson |
|---|---|
| Speciality | General Practice |
| Location | 525 Branson Landing Blvd, Branson, Missouri |
| Authorized Official Name and Position | Robert L Ferguson (VICE PRESIDENT) |
| Authorized Official Contact | 4178753311 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Ferrell-duncan Clinic Branson Po Box 9007 Accounting Springfield MO 65808-9007 Ph: (417) 875-3332 | Ferrell-duncan Clinic Branson 525 Branson Landing Blvd Branson MO 65616-2031 Ph: (417) 875-3332 |
| NPI Number | 1174952212 |
|---|---|
| Provider Enumeration Date | 11/08/2013 |
| Last Update Date | 03/12/2020 |
| Medicare PECOS PAC ID | 1658509864 |
|---|---|
| Medicare Enrollment ID | O20140115001602 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174952212 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | Anthony L Wheeler |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275531683 PECOS PAC ID: 3779489075 Enrollment ID: I20040217000411 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Richard S Makuch |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1497753446 PECOS PAC ID: 3870499171 Enrollment ID: I20040323000296 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Gregg J Salathe |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1346391778 PECOS PAC ID: 8820070196 Enrollment ID: I20040602000559 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Mosbah M Kreimid |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1558347237 PECOS PAC ID: 6608829411 Enrollment ID: I20050222000025 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Rodney Mcfadden |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1831293547 PECOS PAC ID: 8527966985 Enrollment ID: I20050301000079 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Raymond Lobins |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1356391064 PECOS PAC ID: 2567368673 Enrollment ID: I20050314000016 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Brenda G Scheiderer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689771719 PECOS PAC ID: 3678523230 Enrollment ID: I20050405000002 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | John R Driver |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1790770451 PECOS PAC ID: 6507813946 Enrollment ID: I20050608001041 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Zachary C Schmittling |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1043254519 PECOS PAC ID: 0042254690 Enrollment ID: I20050614001055 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Jennifer K Lynch |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1700829165 PECOS PAC ID: 0547204109 Enrollment ID: I20050614001107 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | John Mullins |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1396784377 PECOS PAC ID: 9436189750 Enrollment ID: I20050817000006 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Papaiah Sreepada |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1063452803 PECOS PAC ID: 3779513015 Enrollment ID: I20050817000101 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Arthur Hawes |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1992743041 PECOS PAC ID: 8729018528 Enrollment ID: I20050820000101 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Steven Otto |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1154364289 PECOS PAC ID: 3870523681 Enrollment ID: I20050820000136 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Jose Dominguez |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1295773927 PECOS PAC ID: 5597795302 Enrollment ID: I20050820000146 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Terrence Coulter |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1477591303 PECOS PAC ID: 3476583287 Enrollment ID: I20050822000012 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Joseph S. Field |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1700822244 PECOS PAC ID: 4486647922 Enrollment ID: I20051219000933 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Boyd D Crockett |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1427166537 PECOS PAC ID: 7012019391 Enrollment ID: I20070219000056 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Charles T Fielder |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1740200369 PECOS PAC ID: 3173577590 Enrollment ID: I20070619000156 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Wayne Putnam |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1275604621 PECOS PAC ID: 4284735697 Enrollment ID: I20070803000390 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Robert W Vorhies |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1730163452 PECOS PAC ID: 6901862911 Enrollment ID: I20080111000228 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Jerry S Givens |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1164462412 PECOS PAC ID: 6103904578 Enrollment ID: I20080425000092 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Mitchell A Ahrens |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1407967235 PECOS PAC ID: 9931288073 Enrollment ID: I20080430000896 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | James Alton Ragland |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1619148053 PECOS PAC ID: 4284703489 Enrollment ID: I20080514000155 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Veeral Bhoot |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1598982167 PECOS PAC ID: 0345227898 Enrollment ID: I20080812000187 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Mittie M Dragosljvich |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1851408934 PECOS PAC ID: 1355448812 Enrollment ID: I20080812000335 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Ibrahim I Abdalla |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1437154630 PECOS PAC ID: 4183785736 Enrollment ID: I20081202000201 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Michael A Albritton |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1548264971 PECOS PAC ID: 1951462514 Enrollment ID: I20081202000261 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | William Micka |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1376689729 PECOS PAC ID: 2163573999 Enrollment ID: I20090707000640 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Lance H Borup |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1356320436 PECOS PAC ID: 4789682956 Enrollment ID: I20090820000501 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | George S Brehm |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1427001460 PECOS PAC ID: 3173670767 Enrollment ID: I20100423000893 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Alexander R Hover |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1144398256 PECOS PAC ID: 7214072156 Enrollment ID: I20100816000344 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Shelli J Mabe |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1992715692 PECOS PAC ID: 8628245859 Enrollment ID: I20120111000562 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Minh Thu N Le |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1174559116 PECOS PAC ID: 0143485235 Enrollment ID: I20120621000679 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Anees Afroze |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1043352057 PECOS PAC ID: 4587810759 Enrollment ID: I20120804000040 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Brett W Hronek |
|---|---|
| Provider Type | Practitioner - Allergy/immunology |
| Provider Identifiers | NPI Number: 1275791568 PECOS PAC ID: 5799963054 Enrollment ID: I20120820000975 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Amy R Ford Turner |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1710188040 PECOS PAC ID: 7416117056 Enrollment ID: I20130814000960 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Ricky J Deville |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1457692857 PECOS PAC ID: 7719121284 Enrollment ID: I20130924000163 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Dirk Mcmurray |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1629207840 PECOS PAC ID: 7517133440 Enrollment ID: I20140528002177 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Jason M Haas |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1790948008 PECOS PAC ID: 8022232883 Enrollment ID: I20140617002213 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Nicholas Andrew Madden |
|---|---|
| Provider Type | Practitioner - Radiation Oncology |
| Provider Identifiers | NPI Number: 1083903785 PECOS PAC ID: 9133444813 Enrollment ID: I20150223000263 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Donald W Myears |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1487045647 PECOS PAC ID: 0941526867 Enrollment ID: I20150311001328 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Boone Wilford |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1487044962 PECOS PAC ID: 6103143300 Enrollment ID: I20150327001257 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Jessica A Hanson |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1013203553 PECOS PAC ID: 7719295021 Enrollment ID: I20151007001184 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Cecilia Hiromi Yshii Tamashiro |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1750518080 PECOS PAC ID: 5496994154 Enrollment ID: I20151203001820 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Gwen C Pead |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1316303993 PECOS PAC ID: 9830498757 Enrollment ID: I20160512001630 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Sarah Hossain |
|---|---|
| Provider Type | Practitioner - Gastroenterology |
| Provider Identifiers | NPI Number: 1639478662 PECOS PAC ID: 0446493050 Enrollment ID: I20160622000895 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Srikant Nannapaneni |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1407174782 PECOS PAC ID: 5193016178 Enrollment ID: I20160622001131 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Mark Mason |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1386930626 PECOS PAC ID: 5597905604 Enrollment ID: I20170612001486 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Lacey R Vanemburg |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1104366228 PECOS PAC ID: 9830460302 Enrollment ID: I20180219002089 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Steven Phillip Ellis |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1821431123 PECOS PAC ID: 2365732427 Enrollment ID: I20180607001176 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Rakesh Hegde |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1164759924 PECOS PAC ID: 3577823244 Enrollment ID: I20180730002653 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Sarah Catherine Boss |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1467939280 PECOS PAC ID: 1658629415 Enrollment ID: I20180810000220 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Philipp Alexander Wiesner |
|---|---|
| Provider Type | Practitioner - Interventional Cardiology |
| Provider Identifiers | NPI Number: 1609162817 PECOS PAC ID: 8224371885 Enrollment ID: I20190522001650 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | None Vimal Ravi |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1578996419 PECOS PAC ID: 4688975428 Enrollment ID: I20190628000166 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Amanda J Fischer |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1013335405 PECOS PAC ID: 9335440270 Enrollment ID: I20190909003352 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Karim Welaya |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1841600491 PECOS PAC ID: 1355640053 Enrollment ID: I20200602002954 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Connor Barnes |
|---|---|
| Provider Type | Practitioner - Plastic And Reconstructive Surgery |
| Provider Identifiers | NPI Number: 1568881407 PECOS PAC ID: 4183045792 Enrollment ID: I20200608002489 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Kathryn Cameron |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1578828455 PECOS PAC ID: 4789974767 Enrollment ID: I20200615000576 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Alex Andrew Henderson |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1336521764 PECOS PAC ID: 2264745652 Enrollment ID: I20200706002345 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Benjamin Lisle |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598143505 PECOS PAC ID: 1951619766 Enrollment ID: I20200730001609 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Rajesh Banderudrappagari |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1093094260 PECOS PAC ID: 3173849742 Enrollment ID: I20201112002736 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Aaron Timothy Murray |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1265600753 PECOS PAC ID: 7113174087 Enrollment ID: I20210622001987 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Brittany Woodall |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1548837404 PECOS PAC ID: 7719388933 Enrollment ID: I20210625000943 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Alexandria Placencia |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1538620430 PECOS PAC ID: 5496080186 Enrollment ID: I20210712002191 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Megan Elizabeth Nicolas |
|---|---|
| Provider Type | Practitioner - Colorectal Surgery (proctology) |
| Provider Identifiers | NPI Number: 1427439322 PECOS PAC ID: 5496062259 Enrollment ID: I20210809001963 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Hasan Bit-shawish |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1871702779 PECOS PAC ID: 5395845457 Enrollment ID: I20211112001052 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Douglas Wayne Hughes |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1659376739 PECOS PAC ID: 4587628102 Enrollment ID: I20220120001509 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Kevin Hal Liljenquist |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1952041790 PECOS PAC ID: 6507246832 Enrollment ID: I20220705001826 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Patrick Barnett |
|---|---|
| Provider Type | Practitioner - Anesthesiology |
| Provider Identifiers | NPI Number: 1366853384 PECOS PAC ID: 6406072594 Enrollment ID: I20220721000678 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Stephen R Gallo |
|---|---|
| Provider Type | Practitioner - Vascular Surgery |
| Provider Identifiers | NPI Number: 1710368725 PECOS PAC ID: 1850775180 Enrollment ID: I20230426000266 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Cody Lee Haerther |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1417682238 PECOS PAC ID: 8224498027 Enrollment ID: I20230712000616 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Leanna Thomas |
|---|---|
| Provider Type | Practitioner - Certified Registered Nurse Anesthetist (crna) |
| Provider Identifiers | NPI Number: 1457086258 PECOS PAC ID: 3375905300 Enrollment ID: I20230808002752 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
| Provider Name | Paolo Soriano |
|---|---|
| Provider Type | Practitioner - Hematology/oncology |
| Provider Identifiers | NPI Number: 1932581022 PECOS PAC ID: 9335451244 Enrollment ID: I20230828000885 |
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
News Archive
Adults with lupus who report having had adverse childhood experiences, such as abuse, neglect and household challenges, report higher disease activity, depression and poorer overall health compared to those without such experiences, according to a study by researchers at UC San Francisco.
America has the highest maternal mortality rate in the developed world, and it's getting worse. Since cardiovascular disease is the primary cause, researchers at the University of Pittsburgh School of Medicine and the Magee-Womens Research Institute created a blood pressure home-monitoring program to rapidly detect concerning trends in postpartum women before their situation becomes critical.
AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.
› Verified 2 days ago
Skaggs South Pointe Medical Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2461 State Highway 165, Suite E, Branson, MO 65616 Phone: 417-348-8964 Fax: 417-336-0275 | |
Premier Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 895 State Highway 248, Branson, MO 65616 Phone: 417-336-5100 Fax: 417-336-5107 | |
Skaggs Family Health Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 545 Branson Landing Blvd, Suite 504, Branson, MO 65616 Phone: 417-335-7540 Fax: 417-335-7544 | |
Skaggs Center For Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 545 Branson Landing Blvd, Suite 401, Branson, MO 65616 Phone: 417-335-7000 Fax: 417-335-7588 | |
Coxhealth Family Medicine & Obstetrics Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 525 Branson Landing Blvd Ste 508, Branson, MO 65616 Phone: 417-335-7540 Fax: 417-335-7544 | |
Drs Family Medical Clinic, Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 118 N 3rd St, Branson, MO 65616 Phone: 417-334-3655 Fax: 417-334-3614 | |
Skaggs Roark Valley Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 121 Cahill Rd, Suite 201, Branson, MO 65616 Phone: 417-335-7555 Fax: 417-335-7588 |